SpaceXAI to Double Nvidia Chips at Colossus 2 by Year-End 
TikTok Reaches $100 Million Alabama Settlement Over Child Safety Claims 
OpenAI to Preview GPT-6 Cyber AI Model for Cybersecurity 
China Agrees to Buy 20 Million Tons of U.S. Coal 
US Appeals Court Upholds Anthropic AI Supply Chain Ban 
AMD Hits $1 Trillion as BofA Raises Price Target to $720 
South Korea Tax Windfall Could Top 50 Trillion Won on Chip Boom 
TSMC Accelerates 2nm Expansion as AI Chip Demand Surges 
Europe’s AI Data Centre Boom Strengthens Case for Nuclear Power 
Germany’s 2026 Growth Outlook Strengthens on Fiscal Spending 
European Stocks Fall as Bond Yields and Geopolitical Risks Weigh 
Oil Prices Fall on U.S.-Iran Hormuz Deal Hopes 
Asian Chip Stocks Tumble as OpenAI Safety Pause Sparks AI Growth Concerns 
Hong Kong Home Prices Stabilize in August After July Decline 
Nissan Targets US Hybrid Growth With Rogue e-Power Launch 
Trump to Ease U.S. Fuel-Economy Standards 
Jeff Bezos Invests $32 Billion in Blue Origin as Space Firm Targets Major Growth 
Add as a preferred source on Google
Cresco Labs Inc. and Columbia Care are cannabis and medical marijuana companies that have previously announced their merger through an acquisition deal. In March 2022, they agreed to a transaction that would have created the largest cannabis operator in the United States, but the agreement seems to have gone up in smoke.
Cresco Labs and Columbia made a new announcement on Monday, July 31, stating they have terminated their $2 billion merger deal. This development comes as the industry is waiting for banking reforms, as per CNBC.
Moreover, it was suggested that the contract has been called off as the cannabis industry has been showing indications of a slowdown as it also deals with various economic issues and challenges with regulators. The cannabis companies mutually agreed to scrap their agreement, so there will be no penalties or fees to pay for both parties.
Another reason for the failure of the merger is the fact that Cresco Labs and Columbia Care were not able to unload enough assets required to secure the regulators' seal of approval. They were given the June 30 deadline for this but failed to comply.
"In light of the evolving landscape in the cannabis industry, we believe the decision to terminate the planned transaction is in the long-term interest of Cresco Labs and our shareholders," Cresco Labs' co-founder and chief executive officer, Charles Bachtell, said in a press release.
"We want to express our sincere gratitude to Columbia Care for their valuable collaboration and dedication during this transaction. While this is not the outcome we originally hoped for, we are confident Cresco Labs is in a stronger position moving forward."
Columbia Care's co-founder and CEO, Nicholas Vita, added, "After careful consideration, we are confident in the mutual decision to move forward as separate, standalone companies. This is the best path forward for Columbia Care's employees, customers, and shareholders. We are thankful for the collaboration and partnership with the Cresco team throughout this extensive process."
Photo by: Kimzy Nanney/Unsplash
